A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity scoreanalysis.

Mario Cottone, Antonio Carroccio, Sebastiano Siringo, Filippo Mocciaro, Sara Renna, Rosalba Orlando, Fabio Salvatore Macaluso, Antonio Carroccio, Marco Mendolaro, Dario Pluchino, Marco Ventimiglia, Serena Garufi, Concetta Ferracane, Valentina Pisana, Antonio Carroccio, Sebastiano Siringo, Antonio Magnano, Gaetano Inserra, Roberto Di Mitri, Antonino Carlo PriviteraAntonio Magnano, Ambrogio Orlando, Walter Fries, Maria Cappello, Giuseppe Scarpulla

Risultato della ricerca: Article

2 Citazioni (Scopus)

Abstract

BACKGROUND:Adalimumab and golimumab are effective in the treatment of moderate to severe ulcerative colitis.AIMS:We reported the comparative effectiveness of adalimumab and golimumab in ulcerative colitis.METHODS:118 patients treated with adalimumab and 79 treated with golimumab were included and evaluated at 8 weeks and at the end of follow up.RESULTS:Overall clinical benefit was 72.6% at 8 weeks and 58.9% at the end of follow up. Patients with longer disease duration and those treated with adalimumab had a better outcome. Clinical benefit was 78.8% in adalimumab patients and 63.3% in golimumab patients (p = 0.026) after 8 weeks; it was 66.9% in adalimumab patients and 46.8% in golimumab patients (p = 0.008) at the end of follow up. These data were confirmed by propensity score analysis. A further analysis considering adalimumab optimization as treatment failure showed that the difference between adalimumab and golimumab was not significant.CONCLUSION:Adalimumab and golimumab are effective in the treatment of ulcerative colitis. Adalimumab seems to be more effective than golimumab. This difference is probably affected by the impossibility of golimumab to be optimized in Italy while adalimumab is.
Lingua originaleEnglish
pagine (da-a)1292-1298
Numero di pagine7
RivistaDigestive and Liver Disease
Volume50
Stato di pubblicazionePublished - 2018

Fingerprint

Ulcerative Colitis
Adalimumab
golimumab
Propensity Score
Treatment Failure
Italy

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Cita questo

A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity scoreanalysis. / Cottone, Mario; Carroccio, Antonio; Siringo, Sebastiano; Mocciaro, Filippo; Renna, Sara; Orlando, Rosalba; Macaluso, Fabio Salvatore; Carroccio, Antonio; Mendolaro, Marco; Pluchino, Dario; Ventimiglia, Marco; Garufi, Serena; Ferracane, Concetta; Pisana, Valentina; Carroccio, Antonio; Siringo, Sebastiano; Magnano, Antonio; Inserra, Gaetano; Di Mitri, Roberto; Privitera, Antonino Carlo; Magnano, Antonio; Orlando, Ambrogio; Fries, Walter; Cappello, Maria; Scarpulla, Giuseppe.

In: Digestive and Liver Disease, Vol. 50, 2018, pag. 1292-1298.

Risultato della ricerca: Article

Cottone, M, Carroccio, A, Siringo, S, Mocciaro, F, Renna, S, Orlando, R, Macaluso, FS, Carroccio, A, Mendolaro, M, Pluchino, D, Ventimiglia, M, Garufi, S, Ferracane, C, Pisana, V, Carroccio, A, Siringo, S, Magnano, A, Inserra, G, Di Mitri, R, Privitera, AC, Magnano, A, Orlando, A, Fries, W, Cappello, M & Scarpulla, G 2018, 'A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity scoreanalysis.', Digestive and Liver Disease, vol. 50, pagg. 1292-1298.
Cottone, Mario ; Carroccio, Antonio ; Siringo, Sebastiano ; Mocciaro, Filippo ; Renna, Sara ; Orlando, Rosalba ; Macaluso, Fabio Salvatore ; Carroccio, Antonio ; Mendolaro, Marco ; Pluchino, Dario ; Ventimiglia, Marco ; Garufi, Serena ; Ferracane, Concetta ; Pisana, Valentina ; Carroccio, Antonio ; Siringo, Sebastiano ; Magnano, Antonio ; Inserra, Gaetano ; Di Mitri, Roberto ; Privitera, Antonino Carlo ; Magnano, Antonio ; Orlando, Ambrogio ; Fries, Walter ; Cappello, Maria ; Scarpulla, Giuseppe. / A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity scoreanalysis. In: Digestive and Liver Disease. 2018 ; Vol. 50. pagg. 1292-1298.
@article{7f2d21820298401384e32a702878bc2f,
title = "A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity scoreanalysis.",
abstract = "BACKGROUND:Adalimumab and golimumab are effective in the treatment of moderate to severe ulcerative colitis.AIMS:We reported the comparative effectiveness of adalimumab and golimumab in ulcerative colitis.METHODS:118 patients treated with adalimumab and 79 treated with golimumab were included and evaluated at 8 weeks and at the end of follow up.RESULTS:Overall clinical benefit was 72.6{\%} at 8 weeks and 58.9{\%} at the end of follow up. Patients with longer disease duration and those treated with adalimumab had a better outcome. Clinical benefit was 78.8{\%} in adalimumab patients and 63.3{\%} in golimumab patients (p = 0.026) after 8 weeks; it was 66.9{\%} in adalimumab patients and 46.8{\%} in golimumab patients (p = 0.008) at the end of follow up. These data were confirmed by propensity score analysis. A further analysis considering adalimumab optimization as treatment failure showed that the difference between adalimumab and golimumab was not significant.CONCLUSION:Adalimumab and golimumab are effective in the treatment of ulcerative colitis. Adalimumab seems to be more effective than golimumab. This difference is probably affected by the impossibility of golimumab to be optimized in Italy while adalimumab is.",
author = "Mario Cottone and Antonio Carroccio and Sebastiano Siringo and Filippo Mocciaro and Sara Renna and Rosalba Orlando and Macaluso, {Fabio Salvatore} and Antonio Carroccio and Marco Mendolaro and Dario Pluchino and Marco Ventimiglia and Serena Garufi and Concetta Ferracane and Valentina Pisana and Antonio Carroccio and Sebastiano Siringo and Antonio Magnano and Gaetano Inserra and {Di Mitri}, Roberto and Privitera, {Antonino Carlo} and Antonio Magnano and Ambrogio Orlando and Walter Fries and Maria Cappello and Giuseppe Scarpulla",
year = "2018",
language = "English",
volume = "50",
pages = "1292--1298",
journal = "Digestive and Liver Disease",
issn = "1590-8658",
publisher = "Elsevier",

}

TY - JOUR

T1 - A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity scoreanalysis.

AU - Cottone, Mario

AU - Carroccio, Antonio

AU - Siringo, Sebastiano

AU - Mocciaro, Filippo

AU - Renna, Sara

AU - Orlando, Rosalba

AU - Macaluso, Fabio Salvatore

AU - Carroccio, Antonio

AU - Mendolaro, Marco

AU - Pluchino, Dario

AU - Ventimiglia, Marco

AU - Garufi, Serena

AU - Ferracane, Concetta

AU - Pisana, Valentina

AU - Carroccio, Antonio

AU - Siringo, Sebastiano

AU - Magnano, Antonio

AU - Inserra, Gaetano

AU - Di Mitri, Roberto

AU - Privitera, Antonino Carlo

AU - Magnano, Antonio

AU - Orlando, Ambrogio

AU - Fries, Walter

AU - Cappello, Maria

AU - Scarpulla, Giuseppe

PY - 2018

Y1 - 2018

N2 - BACKGROUND:Adalimumab and golimumab are effective in the treatment of moderate to severe ulcerative colitis.AIMS:We reported the comparative effectiveness of adalimumab and golimumab in ulcerative colitis.METHODS:118 patients treated with adalimumab and 79 treated with golimumab were included and evaluated at 8 weeks and at the end of follow up.RESULTS:Overall clinical benefit was 72.6% at 8 weeks and 58.9% at the end of follow up. Patients with longer disease duration and those treated with adalimumab had a better outcome. Clinical benefit was 78.8% in adalimumab patients and 63.3% in golimumab patients (p = 0.026) after 8 weeks; it was 66.9% in adalimumab patients and 46.8% in golimumab patients (p = 0.008) at the end of follow up. These data were confirmed by propensity score analysis. A further analysis considering adalimumab optimization as treatment failure showed that the difference between adalimumab and golimumab was not significant.CONCLUSION:Adalimumab and golimumab are effective in the treatment of ulcerative colitis. Adalimumab seems to be more effective than golimumab. This difference is probably affected by the impossibility of golimumab to be optimized in Italy while adalimumab is.

AB - BACKGROUND:Adalimumab and golimumab are effective in the treatment of moderate to severe ulcerative colitis.AIMS:We reported the comparative effectiveness of adalimumab and golimumab in ulcerative colitis.METHODS:118 patients treated with adalimumab and 79 treated with golimumab were included and evaluated at 8 weeks and at the end of follow up.RESULTS:Overall clinical benefit was 72.6% at 8 weeks and 58.9% at the end of follow up. Patients with longer disease duration and those treated with adalimumab had a better outcome. Clinical benefit was 78.8% in adalimumab patients and 63.3% in golimumab patients (p = 0.026) after 8 weeks; it was 66.9% in adalimumab patients and 46.8% in golimumab patients (p = 0.008) at the end of follow up. These data were confirmed by propensity score analysis. A further analysis considering adalimumab optimization as treatment failure showed that the difference between adalimumab and golimumab was not significant.CONCLUSION:Adalimumab and golimumab are effective in the treatment of ulcerative colitis. Adalimumab seems to be more effective than golimumab. This difference is probably affected by the impossibility of golimumab to be optimized in Italy while adalimumab is.

UR - http://hdl.handle.net/10447/364545

M3 - Article

VL - 50

SP - 1292

EP - 1298

JO - Digestive and Liver Disease

JF - Digestive and Liver Disease

SN - 1590-8658

ER -